Ablative Therapies for Early Stage Kidney Cancer and the Evolving Role of the Urologist

Percutaneous ablation has become the most common ablative modality for early stage kidney cancer. Although percutaneous ablation carries a more favorable safety profile, posttreatment morbidity occurs with some frequency, highlighting the need for continued urologist engagement.